Pharmaceutical Change Control Management: Cross-Functional Impact Assessment, CMC & Regulatory Filing Triggers

Uncontrolled changes to manufacturing processes, raw material suppliers, equipment components, analytical test methods, or packaging specifications are the root cause of batch failures and FDA warning letters. Quality management regulations mandate that all modifications undergo documented review, risk analysis, and regulatory assessment before implementation.

Novaqis QMS enforces automated cross-functional assessments across five core disciplines: • Manufacturing & Engineering: Equipment qualification impact, utility changes, cleanroom airflow modifications. • Analytical & QC: Method validation requirements, new reference standards, STP revisions. • Regulatory Affairs (CMC): Identification of regulatory filing triggers (Prior Approval Supplement - PAS, Changes Being Effected in 30 Days - CBE-30, Annual Report, or EU Type IA/IB/II variations). • Stability Commitment: Protocol initiation requirements for 3 pilot or commercial batches under accelerated and long-term conditions per ICH Q1A. • Documentation & Training: Identification of affected SOPs in Novaqis DMS and mandatory retraining curricula in Novaqis LMS.

A change control cannot be closed upon simple task completion. Novaqis QMS requires a predefined post-implementation review (typically 3–6 months post-effective date) to verify that process capability (Cpk) remained stable, no unexpected deviations arose, and intended quality improvements were verified.